<DOC>
	<DOCNO>NCT00478595</DOCNO>
	<brief_summary>The primary objective study assess efficacy Rimonabant ( SR141716 ) compare placebo change HbA1c relative change body weight 52 week obese type 2 diabetic patient monotherapy inadequately control oral anti-diabetic drug ( sulfonylurea α-glucosidase inhibitor ) . The secondary objective : - To evaluate effect Rimonabant compare placebo parameter relate glucose control , waist circumference , Body Mass Index metabolic parameter ; - To evaluate safety tolerability Rimonabant compare placebo ; - To evaluate pharmacokinetics Rimonabant .</brief_summary>
	<brief_title>Japanese Study With Rimonabant Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug</brief_title>
	<detailed_description>The total duration per patient approximately 69 week include 52-week double-blind treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Type 2 Diabetes Mellitus patient monotherapy oral antidiabetic drug ( sulfonylurea αglucosidase inhibitor ) HbA1C ≥ 7.0 % ≤ 10.0 % Body Mass Index ≥ 25 kg/m² Type 1 diabetes Within 12 week prior screen visit : use oral antidiabetic drug ( sulfonylurea alphaglucosidase inhibitor ) and/or insulin , antiobesity drug drug weight reduction Within 4 week prior screen visit : administration systemic longacting corticosteroid prolong use ( one week ) systemic corticosteroid , change lipid lower treatment Secondary obesity Primary hyperlipidemia Positive serum pregnancy test female childbearing potential The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>obese</keyword>
	<keyword>diabetes</keyword>
	<keyword>cannabinoid-1 receptor</keyword>
</DOC>